Key Highlights
- Total Revenue rose 15% to USD 151.8 million from USD 131.9 million in the third quarter, with testing revenue also up 15% to USD 146.4 million.
- The 2026 testing revenue outlook was lowered to USD 571 million to USD 573 million from USD 576 million to USD 582 million, a midpoint cut of USD 7 million (calculated).
- Decipher Prostate Volume was about 29,900 tests in the quarter, generating USD 92.3 million of revenue, up 12% year over year.
- Market data listed shares down 54.30% in the November 5, 2026 session, a figure from a single listing that was not independently confirmed.
A Beat on the Quarter, a Cut to the Year
Veracyte (NASDAQ:VCYT) released third-quarter results on November 4, 2026, and published market data showed a regular-session fall of 54.30% on November 5. That figure came from a single market listing, so it is treated as reported. Net Income was USD 31.5 million and adjusted EBITDA was USD 41.2 million, up 4% from USD 39.7 million. Market wraps said revenue and Earnings Per Share beat consensus, but management lowered its 2026 testing revenue range and pointed to slower growth in Decipher volume. Total 2026 revenue guidance now sits at USD 590 million to USD 593 million, from USD 590 million to USD 596 million. Testing revenue made up about 96% of the total (calculated).
Decipher Volume Is the Pressure Point
Veracyte sells genomic tests that help doctors decide how to treat cancer, and Decipher Prostate is its largest product. Decipher revenue rose 12% to USD 92.3 million, slower than the company's 15% overall rate. A published wrap also said preliminary 2027 guidance came in well below consensus, but the company release did not contain 2027 figures, so that point is unconfirmed. Diagnostics stocks often trade on test-volume growth because reimbursement is paid per test, and a slower rate resets assumptions about future revenue. The company held USD 370.5 million in cash and short-term investments on September 30, 2026. An adjusted EBITDA Margin of 27.2% shows the Business remains highly profitable, which makes the reaction more about future growth than current earnings.
Reimbursement Doubt and a Sister Drop at MNTN
The same session also saw a 54.68% fall at Advertising software firm MNTN, which cut its 2026 revenue range to USD 311 million to USD 314 million and named a new chief executive. The two moves were unrelated, yet they show how sharply guidance changes are punished. For Veracyte, risks include slower test adoption, payer coverage decisions and a lower multiple on growth that is decelerating. A published wrap also noted a downgrade by a research firm, though the action could not be confirmed. The next markers are the fourth-quarter update, any 2027 outlook the company provides and Decipher volume trends. MNTN reported third-quarter revenue of USD 80.3 million, up 15%, and net income of USD 7.7 million, so its drop was driven by the forecast cut and Leadership change.
Where Things Stand
Veracyte (NASDAQ:VCYT) reportedly crashed because the market looked past the 15% revenue growth to a lower testing revenue range and slower Decipher momentum. The cut itself is modest, about USD 7 million at the midpoint of testing revenue (calculated), so the size of the fall implies investors also reset expectations for 2027 and the growth rate. Profitability remains solid, with a 27.2% adjusted EBITDA margin. The next markers are fourth-quarter volumes and any formal 2027 guidance.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...